The following is a new blog article on the IPIX we
Post# of 72447
(Total Views: 669)
Posted On: 03/06/2020 11:50:21 PM
The following is a new blog article on the IPIX website:
http://www.ipharminc.com/new-blog/2020/3/6/re...-candidate
The following is the beginning of the blog. Click on the link to read the complete blog information including Nature Reviews Drug Discovery article.
March 6, 2020
Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate
Brilacidin
The February 27, 2020, issue of Nature Reviews Drug Discovery, excerpted below, contains a comprehensive review article highlighting the emerging potential clinical applications of Cationic Host Defense Peptides (CHDPs), also referred to as Antimicrobial Peptides (AMPs), and their synthetic mimetics, like Brilacidin.
Increasingly at the cutting-edge of medicine, attracting considerable attention among both Pharma and Academia alike, CHDPs exhibit a number of distinct and highly favorable therapeutic characteristics—anti-bacterial, anti-inflammatory, anti-fungal, anti-biofilm, anti-cancer, and antiviral.
Brilacidin, the Company’s defensin-mimetic drug candidate, has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in multiple FDA clinical trials, and is currently being evaluated as a potential novel coronavirus (COVID-19) treatment.
http://www.ipharminc.com/new-blog/2020/3/6/re...-candidate
http://www.ipharminc.com/new-blog/2020/3/6/re...-candidate
The following is the beginning of the blog. Click on the link to read the complete blog information including Nature Reviews Drug Discovery article.
March 6, 2020
Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate
Brilacidin
The February 27, 2020, issue of Nature Reviews Drug Discovery, excerpted below, contains a comprehensive review article highlighting the emerging potential clinical applications of Cationic Host Defense Peptides (CHDPs), also referred to as Antimicrobial Peptides (AMPs), and their synthetic mimetics, like Brilacidin.
Increasingly at the cutting-edge of medicine, attracting considerable attention among both Pharma and Academia alike, CHDPs exhibit a number of distinct and highly favorable therapeutic characteristics—anti-bacterial, anti-inflammatory, anti-fungal, anti-biofilm, anti-cancer, and antiviral.
Brilacidin, the Company’s defensin-mimetic drug candidate, has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in multiple FDA clinical trials, and is currently being evaluated as a potential novel coronavirus (COVID-19) treatment.
http://www.ipharminc.com/new-blog/2020/3/6/re...-candidate
(11)
(0)